GANX logo

Gain Therapeutics (GANX) Company Overview

Profile

Full Name:

Gain Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 19, 2021

Indexes:

Not included

Description:

Gain Therapeutics (GANX) focuses on developing innovative therapies for neurodegenerative diseases. Using a unique approach, they enhance protein function to treat conditions like Alzheimer's and Parkinson's. Their goal is to create effective treatments that improve patients' quality of life through advanced drug discovery techniques.

Events Calendar

Earnings

Next earnings date:

Mar 26, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 24, 24 Roth MKM
Buy
Dec 5, 24 Roth MKM
Buy
Nov 25, 24 HC Wainwright & Co.
Buy
Oct 9, 24 HC Wainwright & Co.
Buy
Oct 1, 24 HC Wainwright & Co.
Buy
Sep 3, 24 HC Wainwright & Co.
Buy
Aug 9, 24 Chardan Capital
Buy
Jul 11, 24 HC Wainwright & Co.
Buy
Jul 2, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Gain Therapeutics?
  • Does Gain Therapeutics pay dividends?
  • What sector is Gain Therapeutics in?
  • What industry is Gain Therapeutics in?
  • What country is Gain Therapeutics based in?
  • When did Gain Therapeutics go public?
  • Is Gain Therapeutics in the S&P 500?
  • Is Gain Therapeutics in the NASDAQ 100?
  • Is Gain Therapeutics in the Dow Jones?
  • When was Gain Therapeutics's last earnings report?
  • When does Gain Therapeutics report earnings?
  • Should I buy Gain Therapeutics stock now?

What is the ticker symbol for Gain Therapeutics?

The ticker symbol for Gain Therapeutics is NASDAQ:GANX

Does Gain Therapeutics pay dividends?

No, Gain Therapeutics does not pay dividends

What sector is Gain Therapeutics in?

Gain Therapeutics is in the Healthcare sector

What industry is Gain Therapeutics in?

Gain Therapeutics is in the Biotechnology industry

What country is Gain Therapeutics based in?

Gain Therapeutics is headquartered in United States

When did Gain Therapeutics go public?

Gain Therapeutics's initial public offering (IPO) was on March 19, 2021

Is Gain Therapeutics in the S&P 500?

No, Gain Therapeutics is not included in the S&P 500 index

Is Gain Therapeutics in the NASDAQ 100?

No, Gain Therapeutics is not included in the NASDAQ 100 index

Is Gain Therapeutics in the Dow Jones?

No, Gain Therapeutics is not included in the Dow Jones index

When was Gain Therapeutics's last earnings report?

Gain Therapeutics's most recent earnings report was on Nov 14, 2024

When does Gain Therapeutics report earnings?

The next expected earnings date for Gain Therapeutics is Mar 26, 2025

Should I buy Gain Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions